LCM
CGEM icon

Laurion Capital Management’s Cullinan Oncology CGEM Stock Holding History

Laurion Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,000
Closed -$875K – 742
2021
Q1 		$875K Buy
+21,000
New +$853K ﹤0.01% 521

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Laurion Capital Management's CGEM Position: Q2 2021 in Review

Laurion Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2021, closing a stake of 21,000 shares — an estimated $875K sold.

Laurion Capital Management first reported a position in CGEM in Q1 2021 and held it in 1 quarter. The position peaked at $875K in Q1 2021. 71 funds tracked by Wall St. Rank hold CGEM as of Q2 2021.

  • Laurion Capital Management reported no remaining Cullinan Oncology position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 21,000 Cullinan Oncology shares in Q2 2021, an estimated $875K.
  • Laurion Capital Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 1 quarter.
  • Laurion Capital Management's Cullinan Oncology position peaked at $875K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.